IFN-free combination of sofosbuvir and simeprevir for treatment of genotype 1 hepatitis C infection

This review will focus on the efficacy and tolerability of the combination of sofosbuvir and simeprevir in genotype 1 chronic HCV infection. The goal of HCV therapy is to attain cure, which is defined by the US FDA as a sustained virologic response (SVR) or undetectable HCV RNA 12 weeks after HCV therapy, based on data confirming that over 99% patients who achieve this milestone have durable clearance of the infection. SVR12 (undetectable HCV RNA 12 weeks post-treatment) is the mostly commonly used end point to evaluate effectiveness of HCV therapy and will be used interchangeably with SVR in this review. Some of the data presented in this paper are from peer reviewed abstracts presented in major international conferences and are not yet published as manuscripts.